Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices
Key facts
- Who runs it
- Institute of Liver and Biliary Sciences, India
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 104 people enrolled
- Started
- 1 Oct 2021
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Carvedilol
- Standard Medical Treatment
- Record updated
- 20 March 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age 18-65 years
- Liver cirrhosis
- Grade II-III high SAAG ascites
- Small low risk or no esophageal varices
- CTP 7-12
Who cannot take part
- AKI at enrollement (Prior transient volume responsive AKI stage I included)
- Post renal or liver transplantation
- Prior intolerance or S/E to carvedilol or diuretics
- History of CAD, PVD, ventricular arrythmia, Bronchial asthma
- Bilirubin >5 mg/dl
- Age <18 years
- SBP at diagnosis
- Severe Hyponatremia (Na <125 MEq/L)
- Grade II/III/IV HE
- Advanced HCC (BCLC C,D), PVTT, Pregnancy or Lactating mother
- High risk varices (Large varices or small high risk varices)
- CTP >12
- ACLF
- Mixed / TB ascites
- Known CKD, obstructive uropathy
- Patient on MV, NIV, systemic sepsis and shock
- Lack of informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The cumulative risk of refractory ascites is in the order of 20% within five years of the development of ascites. An elevated sinusoidal pressure is essential for the development of ascites, as fluid accumulation does not develop at portal pressure gradient below 8 mm Hg, and rising corrected sinusoidal pressure correlates with decreased 24-hour urinary excretion of sodium.More recently, it has been hypothesised that bacterial translocation associated with portal hypertension in cirrhosis and related pathogen-associated, molecular pattern activated innate immune responses lead to systemic inflammation.This is associated with vasodilatation as well as release of proinflammatory cytokines, reactive oxygen and nitrogen species, contributing to organ dysfunction.This activates sympathetic nervous system stimulating reabsorption of sodium in proximal,distal tubules, loop of Henle and collecting duct as well as the renin-angiotensin-aldosterone system, leading to sodium absorption from distal tubule and collecting duct.[5]Renal sodium retention and eventual free water clearance due to non-osmoticrelease of arginine-vasopressin and its action on V2 receptor in the collectingduct underlie the fluid retention associated with oedema and ascites in cirrhosis.The lowering of portal pressure using non selective beta blocker has also been shown to reduce the development of ascites, refractory ascites and hepatorenal syndrome.Furthermore, the effect of non slective beta blocker on intestinal permeability, bacterial translocation and inflammatory response has been proposed to mitigate the risk of developing spontaneous bacterial peritonitis.
The 2 groups in the trial
- Carvedilol with Standard Medical TreatmentTreatment being tested
Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP \>90, HR \>55.
Treatment: Carvedilol and Standard Medical Treatment
- Standard Medical TreatmentExisting treatment, for comparison
\- Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices- A Randomised Controlled Trial"
- Publications
- Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial).The American journal of gastroenterology, 2026
- Record updated
- 20 March 2025